Latest Recruitment News

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Li-S Energy Limited reported solid progress in its March 2025 quarter, advancing a key collaboration with Kea Aerospace to integrate lithium-sulfur batteries into high-altitude UAVs, while strengthening its board and maintaining a healthy cash position.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.

BauMart Holdings Limited has announced a rights issue to raise approximately $482,000 by offering new shares at a steep discount, aiming to accelerate equipment delivery, fund R&D, and support international recruitment.

BauMart Holdings has unveiled a multi-pronged strategy to tackle construction labour shortages, advance green building materials, and expand mining equipment services, supported by a $482,000 rights issue.

Antipa Minerals has consolidated its Paterson Province tenements into the expansive Minyari Project, resumed full ownership of Wilki and Paterson Projects following partner withdrawals, and launched a major drilling campaign targeting resource growth and new discoveries.

Locality Planning Energy Holdings Ltd (ASX: LPE) reports a cashflow positive nine months to March 2025, confirms no material impact from Cyclone Alfred, and announces key board appointments to support growth.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Hiremii Limited has completed its 2024-25 AI recruitment platform roadmap nine weeks early, with its proprietary AI outperforming industry shortlisting benchmarks. Despite a slight revenue decline due to market slowdowns, the company is poised for growth through technology commercialization and strategic M&A.

Resonance Health reports record $14.9M cash receipts over 12 months and completes cost-cutting measures while advancing two major pharma clinical trials on schedule.

Race Oncology has opened a second Australian clinical site for its Phase 1 trial of RC220 combined with doxorubicin in advanced solid tumours, aiming to speed patient enrolment and gather critical safety and efficacy data.